662116-67-8
662116-67-8 structure
- Name: 4,5-Dichloro-3-nitro-2-pyridinamine
- Chemical Name: 4,5-dichloro-3-nitropyridin-2-amine
- CAS Number: 662116-67-8
- Molecular Formula: C5H3Cl2N3O2
- Molecular Weight: 208.002
- Catalog: Pharmaceutical intermediate Heterocyclic compound Pyridine compound Nitropyridine
- Create Date: 2018-12-31 12:44:54
- Modify Date: 2024-01-09 19:08:09
| Name | 4,5-dichloro-3-nitropyridin-2-amine |
|---|---|
| Synonyms |
2-Pyridinamine, 4,5-dichloro-3-nitro-
2-amino-3-nitro-4,5-dichloropyridine RW3676 4,5-dichloro-3-nitropyridin-2-ylamine 4,5-Dichloro-3-nitro-2-pyridinamine 2-Amino-4,5-dichloro-3-nitropyridine |
| Density | 1.7±0.1 g/cm3 |
|---|---|
| Boiling Point | 337.2±37.0 °C at 760 mmHg |
| Molecular Formula | C5H3Cl2N3O2 |
| Molecular Weight | 208.002 |
| Flash Point | 157.7±26.5 °C |
| Exact Mass | 206.960236 |
| PSA | 85.46000 |
| LogP | 3.18 |
| Vapour Pressure | 0.0±0.7 mmHg at 25°C |
| Index of Refraction | 1.667 |
| Hazard Codes | Xn |
|---|---|
| HS Code | 2933399090 |
|
~84%
662116-67-8 |
| Literature: CANCER RESEARCH TECHNOLOGY LIMITED; BLAGG, Julian; BAVETSIAS, Vassilios; MOORE, Andrew S.; LINARDOPOULOS, Spyridon Patent: WO2013/190319 A1, 2013 ; Location in patent: Paragraph 00118 ; |
|
~54%
662116-67-8 |
| Literature: ASTRAZENECA AB Patent: WO2004/16611 A1, 2004 ; Location in patent: Page 97-98 ; WO 2004/016611 A1 |
|
~26%
662116-67-8 |
| Literature: Bavetsias, Vassilios; Large, Jonathan M.; Sun, Chongbo; Bouloc, Nathalie; Kosmopoulou, Magda; Matteucci, Mizio; Wilsher, Nicola E.; Martins, Vanessa; Reynisson, Johannes; Atrash, Butrus; Faisal, Amir; Urban, Frederique; Valenti, Melanie; De Haven Brandon, Alexis; Box, Gary; Raynaud, Florence I.; Workman, Paul; Eccles, Suzanne A.; Bayliss, Richard; Blagg, Julian; Linardopoulos, Spiros; McDonald, Edward Journal of Medicinal Chemistry, 2010 , vol. 53, # 14 p. 5213 - 5228 |
|
~%
662116-67-8 |
| Literature: Bavetsias, Vassilios; Crumpler, Simon; Sun, Chongbo; Avery, Sian; Atrash, Butrus; Faisal, Amir; Moore, Andrew S.; Brown, Nathan; Sheldrake, Peter W.; Bush, Katherine; Henley, Alan; Box, Gary; Valenti, Melanie; De Haven Brandon, Alexis; Raynaud, Florence I.; Workman, Paul; Eccles, Suzanne A.; Linardopoulos, Spiros; Blagg, Julian; Kosmopoulou, Magda; Bayliss, Richard Journal of Medicinal Chemistry, 2012 , vol. 55, # 20 p. 8721 - 8734,14 Title/Abstract Full Text Show Details Bavetsias, Vassilios; Crumpler, Simon; Sun, Chongbo; Avery, Sian; Atrash, Butrus; Faisal, Amir; Moore, Andrew S.; Kosmopoulou, Magda; Brown, Nathan; Sheldrake, Peter W.; Bush, Katherine; Henley, Alan; Box, Gary; Valenti, Melanie; De Haven Brandon, Alexis; Raynaud, Florence I.; Workman, Paul; Eccles, Suzanne A.; Bayliss, Richard; Linardopoulos, Spiros; Blagg, Julian Journal of Medicinal Chemistry, 2012 , vol. 55, # 20 p. 8721 - 8734 |
|
~%
662116-67-8 |
| Literature: HANMI PHARM. CO., LTD.; LEE, Kyung Ik; SIM, Jae Yi; KIM, Ho Seok; HA, Tae Hee; SUH, Kwee Hyun Patent: WO2013/100631 A1, 2013 ; |
| Precursor 5 | |
|---|---|
| DownStream 1 | |
| HS Code | 2933399090 |
|---|---|
| Summary | 2933399090. other compounds containing an unfused pyridine ring (whether or not hydrogenated) in the structure. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |